Navigating IDEX’s Q2: Understanding Project Delays and Life Science Weakness
Reiterating a ‘Buy’ Rating for IDEX Looking Beyond Near-Term Headwinds Despite facing near-term headwinds in organic revenue and market softness, I firmly believe that IDEX is a strong buy at its current valuation. With a fair price target of $220 per share, the recent acquisition of Mott Corporation for $1 billion has strategically positioned IDEX…